FDA Lifts Clinical Hold on Arbutus AB-101 IND Application
Arbutus said it was notified by the FDA that the clinical hold on its investigational new drug application for AB-101, an oral PD-L1 inhibitor, has been lifted.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA Lifts Clinical Hold on Arbutus Biopharma’s AB-101 IND
Arbutus Biopharma can pursue additional U.S. clinical development of AB-101 after the FDA lifted the hold on its investigational new drug application.